Home » Posts tagged 'cenacitinib'
Tag Archives: cenacitinib
Cenacitinib



Cenacitinib
CAS 2641636-52-2
MF C19H19F2N7O3 MW431.4
Urea, N-[(1R,2S)-2-fluorocyclopropyl]-N′-[5-[(7-fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-
N-{5-[(7-fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)amino]-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl}-N′-[(1R,2S)-2-fluorocyclopropyl]urea
Janus kinase inhibitor, anti-inflammatory, VTX958, VTX 958, SB88R8KGL3
VTX958 for the Treatment of Moderately to Severely Active Crohn’s Disease
CTID: NCT05688852
Phase: Phase 2
Status: Terminated
Date: 2025-07-03
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US323750705&_cid=P22-MKEUDK-45432-1
Example 4: Synthesis of 1-(5-((7-fluoro-2,3-dihydrobenzo[b][1,4]dioxin-5-yl)amino)-7-(methylamino)pyrazolo[1,5-a]pyrimidin-3-yl)-3-((1R,2S)-2-fluorocyclopropyl)urea (5)


| Step 1: To a solution of 1E (100 g, 288 mmol) and 2E (57 g, 345 mmol) in dry 1,4-dioxane (3000 mL) under N 2 atmosphere was added Cs 2CO 3 (141 g, 432 mmol), Pd(OAc) 2 (5.2 g, 23.3 mmol) and BINAP (28.6 g, 46.6 mmol). After stirring at 115° C. overnight, the reaction mixture was cooled to rt. and diluted with hexane (3000 mL). The solid was collected by filtration and washed with 2×1500 mL (50% hexane in DCM). The solid was suspended into 5000 mL water and stirred for 1 h. The solid was collected by filtration and dried under vacuum to afford compound 2 (90 g, 65%) as a brown solid. |
PAT
Publication Number: US-2021139486-A1
Priority Date: 2019-11-08
- Tyk2 pseudokinase ligandsPublication Number: EP-4054581-A1Priority Date: 2019-11-08
- Tyk2 pseudokinase ligandsPublication Number: US-2023348478-A1Priority Date: 2019-11-08
- Substituted pyrazolo[1,5-a]pyrimidines as TYK2 pseudokinase ligandsPublication Number: US-11753411-B2Priority Date: 2019-11-08Grant Date: 2023-09-12
- TYK2 pseudokinase ligandsPublication Number: CN-114929226-BPriority Date: 2019-11-08Grant Date: 2024-09-27
- TYK2 pseudokinase ligandPublication Number: CN-114929226-APriority Date: 2019-11-08
- Preparation of a tyk2 inhibitorPublication Number: WO-2024151992-A1Priority Date: 2023-01-13
- Crystalline forms of a tyk2 inhibitorPublication Number: US-2024010654-A1Priority Date: 2022-07-06
- Crystalline forms of TYK2 inhibitorsPublication Number: CN-119816502-APriority Date: 2022-07-06
- Crystalline forms of a tyk2 inhibitorPublication Number: EP-4551576-A1Priority Date: 2022-07-06
- Crystalline forms of a tyk2 inhibitorPublication Number: WO-2024011136-A1Priority Date: 2022-07-06
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions,Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com



AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

……
//////cenacitinib, cenacitinib, Janus kinase inhibitor, anti-inflammatory, VTX958, VTX 958, SB88R8KGL3
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....










